Diabetic nephropathy
Conditions
Interventions
Research Group:None
Sponsors
The First Affiliated Hospital of Wannan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years and under 85 years; 2. Patients meeting the WHO (2005) diagnostic criteria for diabetes mellitus: (1) Presence of diabetes symptoms with venous plasma glucose concentration >=11.1 mmol/L at any time point. (2) Fasting venous plasma glucose concentration >=7.0 mmol/L. (3) Oral glucose tolerance test (OGTT): venous plasma glucose concentration >=11.1 mmol/L two hours after oral administration of 75 g glucose. Diagnosis of diabetes mellitus is confirmed if any one of the above three criteria is met, and any subsequent repeat test of any one of these three criteria within the following day also meets the criteria. 3. Patients with renal ultrafiltration exceeding 120 mL/min/1.73 m² (eGFR) 4. HbA1c (glycated haemoglobin) >=6% and <12% 5. Signed informed consent form.
Exclusion criteria
Exclusion criteria: Exclude subjects meeting any of the following criteria: 1. Patients currently using SGLT2 inhibitors or SGLT2 inhibitor combination therapies; 2. Type 1 diabetes mellitus; 3. Acute diabetic complications (diabetic ketoacidosis, hyperosmolar diabetic state); 4. Acute clinical cardiovascular events (acute coronary syndrome, prior percutaneous coronary intervention) or hospitalisation for unstable angina within the past 3 months; symptomatic heart failure (NYHA Class IV) within the past 6 months; 5. Hospitalisation within the past 6 months due to extensive cerebral infarction or haemorrhage, presenting with impaired consciousness, hemiplegia, and dysarthria; 6. Symptomatic heart failure within the past 6 months (NYHA Class IV); 7. Expected survival of less than 5 years; 8. Acute infection, trauma, surgery, or other stress states; 9. Concurrent malignant neoplasms; 10. Pregnant or lactating women; 11. Any condition judged by the study physician to compromise study compliance; 12. Failure to sign the written informed consent form; 13. Current participation in another interventional study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glomerular filtration rate;blood glucose; | — |
Secondary
| Measure | Time frame |
|---|---|
| Glycated hemoglobin; | — |
Countries
China
Contacts
Public ContactJialin Gao
The First Affiliated Hospital of Wannan Medical College
Outcome results
None listed